TPO and autoimmune thrombocytopenic purpura: Retrospective studies have shown that the use of TPO-RAs in the treatment of patients with newly diagnosed ITP in daily clinical practice is as effective and safe as it is in chronic ITP [17, 18] and an ongoing clinical trial is currently evaluating this line of treatment in children (NCT03939637).